In Vivo Grade Recombinant Human IgG1 Bispecific Isotype Control Antibody

* CHF, excl. 8.1% VAT and shipping costs

Product Description

The recombinant human IgG1 bispecific isotype control (hIgG1 kappa bispecific isotype control antibody) and mutants are produced in mammalian cells (HEK293 and CHO cells). The recombinant human IgG1 bispecific isotype control has low or no specific binding to any human sample, and humanized or completely human variable regions in addition to the human IgG1 kappa constant regions. The human IgG1 kappa isotype control and mutants such as Fc-silenced can be used in ELISA, Western blot (WB), the cell-based assay or animal model as the antibody negative control.A number of hIgG1 bispecific isotype control mutants are available. Most of the therapeutic antibody drugs carry the natural human IgG1 constant regions. There are some engineered mutants in the IgG1 Fc fragment. Changes to the IgG Fc sequence including glycosylation sites (such as N297A or N297G) have been used to modulate Fc functions. Even a single mutation may have both enhancement and abrogation effects on Fc binding though multiple mutation combinations are commonly used. We generated hIgG1 bispecific isotype control mutants, the same mutations as those in the therapeutic antibodies and candidates because such human IgG1 isotype control mutants are needed when clients test their engineered antibody candid